{
    "organizations": [],
    "uuid": "70e1f6df19a5d410cce0a40b61d36a86eb368f91",
    "author": "",
    "url": "https://www.reuters.com/article/brief-theravance-biopharma-ireland-enter/brief-theravance-biopharma-ireland-enters-global-collaboration-with-janssen-idUSB8N1J4032",
    "ord_in_thread": 0,
    "title": "BRIEF-Theravance Biopharma Ireland Enters Global Collaboration With Janssen",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 00 PM / in 15 minutes BRIEF-Theravance Biopharma Ireland Enters Global Collaboration With Janssen Reuters Staff \nFeb 7 (Reuters) - Theravance Biopharma Ireland Limited: \n* THERAVANCE BIOPHARMA IRELAND LTD - ENTERS GLOBAL COLLABORATION WITH JANSSEN FOR TD-1473 IN INFLAMMATORY INTESTINAL DISEASES \n* THERAVANCE BIOPHARMA - ELIGIBLE FOR UP TO $1 BILLION POTENTIAL PAYMENTS, INCLUDING $100 MILLION UPFRONT \n* THERAVANCE BIOPHARMA - PHASE 2B/3 STUDY IN ULCERATIVE COLITIS, PHASE 2 STUDY IN CROHN’S DISEASE TO BEGIN IN 2018 WITH TD-1473 \n* THERAVANCE BIOPHARMA - WILL LEAD DEVELOPMENT OF TD-1473 IN ULCERATIVE COLITIS THROUGH COMPLETION OF PHASE 2B/3 PROGRAM \n* THERAVANCE BIOPHARMA - AFTER PHASE 2 CROHN’S STUDY, PHASE 2B INDUCTION PORTION OF ULCERATIVE COLITIS STUDY, JANSSEN CAN ENTER EXCLUSIVE LICENSE DEAL \n* THERAVANCE BIOPHARMA - AFTER PHASE 2, JANSSEN WOULD LEAD SUBSEQUENT DEVELOPMENT OF TD-1473 IN CROHN’S DISEASE \n* THERAVANCE BIOPHARMA - JANSSEN CAN ENTER EXCLUSIVE LICENSE DEAL FOR TD-1473 BY PAYING CO $200 MILLION FEE \n* THERAVANCE BIOPHARMA - IF TD-1473 COMMERCIALIZED, CO HAS OPTION TO CO-COMMERCIALIZE IN THE U.S. \n* THERAVANCE BIOPHARMA - IF TD-1473 COMMERCIALIZED, JANSSEN WOULD HAVE SOLE COMMERCIALIZATION RESPONSIBILITIES OUTSIDE U.S. \n* THERAVANCE BIOPHARMA - IF TD-1473 COMMERCIALIZED, CO ELIGIBLE FOR UP TO ADDITIONAL $700 MILLION DEVELOPMENT, COMMERCIALIZATION MILESTONE PAYMENTS Source text for Eikon: Further company coverage:",
    "published": "2018-02-07T17:00:00.000+02:00",
    "crawled": "2018-02-07T17:17:50.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "biopharma",
        "ireland",
        "enters",
        "global",
        "collaboration",
        "janssen",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "theravance",
        "biopharma",
        "ireland",
        "limited",
        "theravance",
        "biopharma",
        "ireland",
        "ltd",
        "enters",
        "global",
        "collaboration",
        "janssen",
        "inflammatory",
        "intestinal",
        "disease",
        "theravance",
        "biopharma",
        "eligible",
        "billion",
        "potential",
        "payment",
        "including",
        "million",
        "upfront",
        "theravance",
        "biopharma",
        "phase",
        "study",
        "ulcerative",
        "colitis",
        "phase",
        "study",
        "crohn",
        "disease",
        "begin",
        "theravance",
        "biopharma",
        "lead",
        "development",
        "ulcerative",
        "colitis",
        "completion",
        "phase",
        "program",
        "theravance",
        "biopharma",
        "phase",
        "crohn",
        "study",
        "phase",
        "2b",
        "induction",
        "portion",
        "ulcerative",
        "colitis",
        "study",
        "janssen",
        "enter",
        "exclusive",
        "license",
        "deal",
        "theravance",
        "biopharma",
        "phase",
        "janssen",
        "would",
        "lead",
        "subsequent",
        "development",
        "crohn",
        "disease",
        "theravance",
        "biopharma",
        "janssen",
        "enter",
        "exclusive",
        "license",
        "deal",
        "paying",
        "co",
        "million",
        "fee",
        "theravance",
        "biopharma",
        "commercialized",
        "co",
        "option",
        "theravance",
        "biopharma",
        "commercialized",
        "janssen",
        "would",
        "sole",
        "commercialization",
        "responsibility",
        "outside",
        "theravance",
        "biopharma",
        "commercialized",
        "co",
        "eligible",
        "additional",
        "million",
        "development",
        "commercialization",
        "milestone",
        "payment",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}